Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

101.43 -2.44 (-2.35%)
Official Closing Price Updated: 7:00 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives
The study examined health care records for more than 41,000 people. 
Via Investor's Business Daily
Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study
A recent extensive analysis by Truveta Research has  
Via Benzinga
Only Have $100? 3 No-Brainer Stocks to Buy Right Now
The stock market is such a well-oiled, wealth-generating machine that investors can start with just $100 to buy these no-brainer stocks. 
Via InvestorPlace
Novo Nordisk's Flexible Pricing Approach: Push for Broader Access, Innovative Payments
Novo Nordisk A/S (NYSE: NVO) is reportedly discussing with healthcare systems to introduce innovative pricing arrangements for its popular weight  
Via Benzinga
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares. 
Via The Motley Fool
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Peering Into Novo Nordisk's Recent Short Interest
Via Benzinga
This Is What Whales Are Betting On Novo Nordisk
Via Benzinga
Google Leads Five S&P 500 Stocks Near Buy Points
Four of the stocks tripped up after earnings, but quickly bounced back. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Could Ozempic Harm These 3 Medical Device Stocks?
The drug is on track to cause massive competitive shifts in the healthcare sector. 
Via The Motley Fool
Novo Nordisk's Wegovy Eyes Asian Market Debut Despite Supply Crunch
Novo Nordisk A/S (NYSE: NVO) reportedly plans to introduce its highly sought-after anti-obesity medication, Wegovy, in Japan on February 22, marking its inaugural entry into the Asian market despite... 
Via Benzinga
7 Stocks Set to Capitalize on the Coming Year-End Rally
The stock market is poised to rally at the year end as multiple positive factors conspire to push certain sectors higher. 
Via InvestorPlace
$3,000 Invested in These 3 Top Stocks Could Make You Rich in 10 Years
Plug into a trio of megatrends with these three particular tickers. 
Via The Motley Fool
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Technical Analysis observations.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Reveals Intriguing Technical Aspects. Here's What You Need to Know. 
Via Chartmill
Better Growth Stock: Novo Nordisk vs. Eli Lilly
These companies have been attracting plenty of attention lately. 
Via The Motley Fool
Emmanuel Macron To Unveil Novo Nordisk Record $2.3B Investment In France's Health Sector
This initiative has been touted as the biggest investment in the health sector ever made during Macron's tenure. 
Via Benzinga
3 Healthcare Stocks to Scoop Up as They Change the Medical Landscape
Consider one of these three leading-edge healthcare stocks from companies focused on significant medical innovations. 
Via InvestorPlace
Ozempic's Surging Demand Has Novo Nordisk Restricting It In Europe, Plus An Older Generation Diabetes Drug: What's Next?
Novo Nordisk A/S (NYSE: NVO) plans to limit starter kit supplies of Ozempic (semaglutide) in Europe and reduce the distribution of Victoza (liraglutide), aiming to bolster Ozempic's production, which... 
Via Benzinga
3 Consumer Goods Stocks That Will Define the Next Decade
These companies can be expected to continue shaping our lives for the foreseeable future thanks to their strong brands. 
Via InvestorPlace
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,... 
Via Benzinga
Topics ETFs
Don't overlook NYSE:NVO—a stock with solid growth prospects and a reasonable valuation.
While growth is established for NYSE:NVO, the stock's valuation remains reasonable. 
Via Chartmill
Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.
New medicines for weight loss and diabetes stand to disrupt the competitive scene. 
Via The Motley Fool
3 Stock-Split Stocks Billionaires Are Buying Hand Over Fist
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three industry-leading stocks that billionaire investors can't stop buying. 
Via The Motley Fool
Eli Lilly Just Got One Step Closer to Dethroning Ozempic. Time to Buy the Stock?
Eli Lilly just received FDA approval for its obesity medication Zepbound, the sister treatment to its blockbuster drug Mounjaro. 
Via The Motley Fool
Exposures Product Safety
GE, Amazon Lead 5 Stocks Near Buy Points With This Bullish Trait
Relative strength is key when choosing top stocks. GE, Amazon meet RS Line Blue Dot screen. 
Via Investor's Business Daily
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
It might have a hard time finding a home in the market. 
Via The Motley Fool
7 A-Rated Retirement Stocks for Your November Buy List
These A-rated retirement stocks represent companies that are stable, reliable, and well-suited for long-term investors. 
Via InvestorPlace
Topics Retirement
Exposures Pension
Pharmaceutical Giant Eli Lilly Plans Expansion In Germany, Eyes Diabetes Drug Production: Report
Eli Lilly And Co (NYSE: LLY) reportedly intends to construct a production plant in western Germany with an estimated investment of €2 billion ($2.17 billion), marking an inaugural substantial... 
Via Benzinga
Why Eli Lilly Stock Flopped While the Market Popped Today
The company is apparently gearing up to spend at least $1 billion on a production facility in Europe. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.